Opendata, web and dolomites

SEPCELL SIGNED

Title of Proposal: Restoring the immune system homeostasis and organ function in severe community acquired pneumonia- induced sepsis through adipose derived allogeneic stem cells (SEPCELL Proje

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SEPCELL project word cloud

Explore the words cloud of the SEPCELL project. It provides you a very rough idea of what is the project "SEPCELL" about.

ascs    clinical    possess    leads    community    exaggerated    dysfunction    infections    reducing    occurrence    treatment    cells    stem    releasing    mediators    anti    unmet    therapy    28    huge    models    innovative    systemic    medical    inflammatory    extensively    hyperactivation    lung    mechanism    multiple    homeostasis    infection    broad    trial    cell    mscs    antimicrobial    acquire    micro    msc    mesenchymal    exacerbated    subsequent    performed    adipose    injury    immunomodulatory    phagocytosis    modulate    initial    thrombosis    reported    normal    treatments    host    cap    immunoparalysis    standard    iib    burden    restoring    possibility    pro    ia    50    immunoactivation    capacities    activation    sepsis    levels    opportunistic    bactericidal    vascular    pneumonia    believes    vasodilatation    patients    organ    peptides    functional    complicated    immune    life    vivo    acute    threatening    patient    complete    social    sepcell    immunosuppression    removal    severe    secondary    pathophysiologic    mediated    re    therapeutic    benefit    mortality    rates    dysregulation    care    allogeneic    experimental    ss   

Project "SEPCELL" data sheet

The following table provides information about the project.

Coordinator
TIGENIX SA 

Organization address
address: CALLE MARCONI 1
city: TRES CANTONS
postcode: 28760
website: http://www.cellerix.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.sepcell.eu/
 Total cost 12˙000˙695 €
 EC max contribution 5˙369˙886 € (45%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-single-stage_RTD
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2020-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TIGENIX SA ES (TRES CANTONS) coordinator 995˙245.00
2    Centre hospitalier universitaire de Limoges FR (Limoges) participant 2˙179˙500.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙071˙790.00
4    CLINIQUES UNIVERSITAIRES SAINT-LUC BE (BRUXELLES) participant 534˙375.00
5    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 297˙678.00
6    TiGENIX NV BE (LEUVEN) participant 291˙297.00

Map

 Project objective

Sepsis is defined as a systemic inflammatory response to infection, while severe sepsis (SS) is a sepsis complicated by acute organ dysfunction. Lung infections, in particular community-acquire pneumonia (CAP), are the leading cause of SS. The pathophysiologic mechanism of CAP-mediated SS is the complete dysregulation of the patient´s immune system. In an initial phase, the systemic hyperactivation of the host immune response against infection leads to high levels of inflammatory mediators, systemic vasodilatation, micro-vascular thrombosis and organ failure. In a second phase, the exaggerated activation of the immune response leads to a state of ‘immunoparalysis’, which is characterized by the occurrence of secondary, opportunistic infections. This makes CAP-mediated SS a life-threatening condition with mortality rates as high as 28-50%. The current standard of care (infection removal and control, functional support) does not improve the high mortality and, thus, CAP-mediated SS represents a major unmet medical need with a huge social burden. Therefore, treatments with the potential to modulate both the initial exacerbated immunoactivation and the subsequent immunosuppression are needed. Mesenchymal stem cells (MSCs), including adipose mesenchymal stem cells (ASCs), are known for their broad range of immunomodulatory properties, targeting multiple pro- and anti-inflammatory pathways, and possess antimicrobial capacities (releasing bactericidal peptides and promoting the phagocytosis by immune cells). Indeed, therapeutic benefit of MSC treatment in in vivo experimental models of sepsis has been extensively reported. The SEPCELL consortium believes that cell therapy with allogeneic ASCs may be an innovative therapeutic approach in order to re-establish the normal immune homeostasis of CAP-mediated SS patients, reducing organ injury and restoring organ functionality. A phase Ia/IIb clinical trial will be performed to test this possibility.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEPCELL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEPCELL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More